Premium
New target in schizophrenia treatment shows promise in 4‐week study
Publication year - 2020
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30601
Subject(s) - schizophrenia (object oriented programming) , exacerbation , medicine , placebo , randomized controlled trial , pharmacology , psychiatry , alternative medicine , pathology
Results of a 4‐week randomized controlled trial suggest progress in identifying a new target for the treatment of schizophrenia. Use of a compound that acts on trace amine‐associated receptor 1 (TAAR1) and 5‐hydroxytryptamine 1A (5‐HT1A) receptors led to greater improvement in symptoms than placebo in a group of 245 patients with an acute exacerbation of schizophrenia. Study results were published in the April 16, 2020, issue of The New England Journal of Medicine .